Dimethyl fumarate

Drug Profile

Dimethyl fumarate

Alternative Names: BG-00012; BG-12; BG-12 oral fumarate; Delayed-release dimethyl fumarate; Delayed-release DMF; FAG-201; Gastro-resistant dimethyl fumarate; Gastro-resistant DMF; Panaclar; Tecfidera

Latest Information Update: 12 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Biogen Idec
  • Class Anti-inflammatories; Antipsoriatics; Cytoprotectives; Esters; Fumarates; Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase I Pulmonary arterial hypertension
  • No development reported Rheumatoid arthritis
  • Discontinued Psoriasis

Most Recent Events

  • 28 Apr 2017 Interim safety and efficacy results from a phase III trial in Multiple sclerosis presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 22 Apr 2017 Interim adverse events data from the phase III ENDORSE extension trial in relapsing-remitting Multiple sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 01 Mar 2017 The US PTO rules against Forward Pharma in the interference proceeding between Forward Pharma’s pending US Patent Application No. 11/576 871 and Biogen’s US Patent No. 8 399 514
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top